Nixon Peabody Trust Co. Invests $3.45 Million in Intuitive Surgical, Inc. $ISRG

Nixon Peabody Trust Co. acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 6,096 shares of the medical equipment provider’s stock, valued at approximately $3,453,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Advisory Alpha LLC increased its position in Intuitive Surgical by 28.5% in the 4th quarter. Advisory Alpha LLC now owns 2,953 shares of the medical equipment provider’s stock worth $1,672,000 after buying an additional 655 shares during the period. Evoke Wealth LLC lifted its holdings in shares of Intuitive Surgical by 43.7% during the fourth quarter. Evoke Wealth LLC now owns 2,744 shares of the medical equipment provider’s stock worth $1,554,000 after buying an additional 835 shares during the last quarter. Principle Wealth Partners LLC boosted its position in shares of Intuitive Surgical by 0.7% in the fourth quarter. Principle Wealth Partners LLC now owns 3,751 shares of the medical equipment provider’s stock valued at $2,124,000 after acquiring an additional 25 shares during the period. Vantage Investment Partners LLC grew its stake in shares of Intuitive Surgical by 0.4% in the fourth quarter. Vantage Investment Partners LLC now owns 16,336 shares of the medical equipment provider’s stock worth $9,252,000 after acquiring an additional 60 shares during the last quarter. Finally, Gradient Capital Advisors LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth $241,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

ISRG opened at $438.10 on Friday. The company has a market capitalization of $155.16 billion, a P/E ratio of 53.10, a P/E/G ratio of 3.51 and a beta of 1.51. The firm’s fifty day moving average price is $458.62 and its two-hundred day moving average price is $510.61. Intuitive Surgical, Inc. has a fifty-two week low of $417.74 and a fifty-two week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.42. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The business’s revenue was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.81 EPS. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 8.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ISRG. HSBC cut their target price on shares of Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Mizuho set a $525.00 price target on shares of Intuitive Surgical and gave the stock a “neutral” rating in a research report on Monday, April 13th. Barclays set a $651.00 price objective on shares of Intuitive Surgical and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Zacks Research cut shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Finally, Leerink Partners decreased their target price on Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Nineteen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $579.33.

Insiders Place Their Bets

In related news, SVP Patricia L. Wadors sold 220 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $499.71, for a total value of $109,936.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mark Brosius sold 645 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $485.01, for a total transaction of $312,831.45. Following the transaction, the senior vice president owned 1,613 shares of the company’s stock, valued at approximately $782,321.13. This represents a 28.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,701 shares of company stock valued at $2,783,807 over the last 90 days. Company insiders own 0.60% of the company’s stock.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive unveiled more than 100 upcoming upgrades for its da Vinci 5 robotic surgery system, including improved force-feedback tools, telecollaboration features, and security/reliability enhancements, which could strengthen the company’s competitive moat and support future procedure growth. Intuitive Surgical’s Da Vinci 5 Upgrades Aim To Deepen Moat For Investors
• Positive Sentiment: Intuitive also announced innovations tied to its “Quintuple Aim” strategy, reinforcing product development momentum and the company’s push to improve surgeon autonomy and operating-room efficiency. Intuitive Announces Innovations to Advance Quintuple Aim
• Positive Sentiment: Wall Street commentary remains moderately optimistic, with analysts still bullish on Intuitive Surgical’s long-term prospects despite recent underperformance versus the broader market. Are Wall Street Analysts Bullish on Intuitive Surgical Stock?
• Neutral Sentiment: Investor interest continues around the SP platform, where strong procedure growth suggests an important future opportunity, but it remains unclear whether this is true addressable-market expansion or mostly a shift within existing robotic procedures. ISRG’s SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
• Neutral Sentiment: There was also minor insider selling by an executive, but the transactions were very small and made under a pre-arranged 10b5-1 plan, so the signal for investors is limited. Mark Brosius insider transaction
• Negative Sentiment: The stock has also been hurt by recent weakness after earnings, with market commentary noting a roughly 7% decline since the last report, reflecting concern that the shares may need more proof of sustained acceleration. Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?
• Negative Sentiment: Several articles also point out that ISRG has significantly lagged the market over the past six months, which may be keeping valuation-sensitive investors on the sidelines. 3 Big Reasons ISRG Should Be On Your Watchlist

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.